Amber Salzman

Amber Salzman serves as CEO at Epicrispr Biotechnologies. Epicrispr Biotechnologies operates in the research sector with approximately 41.0 employees. Epicrispr Biotechnologies generates annual revenue of 1000000.0. To date, Epicrispr Biotechnologies has raised 55000000.0 in total funding, with the most recent round being Series A.

Industry & Role Insights

• • MessageCEO tracks 2,961 executives in the research sector.
• • Our database includes 201,468 c suite-level executives.

Gmail Google Apps Microsoft Office 365 Greenhouse.io Google Cloud Hosting Google Tag Manager Gravity Forms WordPress.org MailChimp Nginx reCAPTCHA Vimeo Mobile Friendly Remote

biotechnology research epigenetic therapy genetic medicine gene modulation customized therapies gene expression epigenome editing crispr technology gene expression modulation system gems platform gene silencing dna-binding proteins guide rnas modulator proteins transcriptional activators transcriptional repressors epigenomic modulators mutation-agnostic therapeutic targets in vivo delivery ex vivo delivery neuromuscular diseases d4z4 methylation facioscapulohumeral muscular dystrophy clinical trials fda clearance biotechnology crispr-cas9 epigenetic editing gene therapy gene regulation molecular biology synthetic biology transcription factors chromatin remodeling gene therapy for rare diseases dcas9 pathogenics precision medicine genome engineering epigenetic biomarkers novel therapies biotherapeutics nuclease-deactivated cas9 therapeutic pipeline next-generation car-t cells protein engineering data science in biotech computational genomics genomic therapies bioengineering advancements health care health wellness & fitness hospital & health care

SN

Srikanth Nandiraju Chief Technology Officer at 1Cell.Ai Inc.

SD

Surinnder Dang Chief Business Officer at 1Cell.Ai Inc.

M

Mark Chief Executive Officer at 23Strands

IT

Ilia Tikhomirov Chief Executive Officer at 35Pharma

AD

Alistair Draffan Chief Executive Officer at 360biolabs Pty Ltd

Outreach Guidance — research Sector

Executives like Amber Salzman in the research sector receive targeted outreach from sales teams, recruiters, and investors. To stand out, personalize your message with industry-specific context and a clear, specific value proposition relevant to their role at Epicrispr Biotechnologies.

Amber Salzman's Position in the MessageCEO Database

• •Amber Salzman is 1 of 1 verified executive contact we track at Epicrispr Biotechnologies.
• •2,871 verified executive contacts in research are in the MessageCEO database.
• •28 verified contacts work at research companies in the 41.0 employee range (same size as Epicrispr Biotechnologies).

Executive contact data compiled from public business filings, LinkedIn public profiles, company press materials, and verified outbound email testing. We do not publish personal addresses or sensitive identifiers. Methodology & sources · Removal requests handled at /remove-info · Updated July 2026.

How do I reach Amber Salzman directly?

Amber Salzman's verified email address is available to MessageCEO Pro subscribers. They currently serve as CEO at Epicrispr Biotechnologies. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does Amber Salzman work for?

Amber Salzman is CEO at Epicrispr Biotechnologies, a company in the research sector with 41.0 employees.

Can I pitch or sell to Amber Salzman?

As CEO at Epicrispr Biotechnologies, Amber Salzman is a key decision-maker in the research sector. MessageCEO Pro gives you verified email to reach Amber Salzman directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is Amber Salzman in?

Amber Salzman works in the research industry as CEO at Epicrispr Biotechnologies. MessageCEO provides verified contact information for executives across all major industries.

Is Amber Salzman's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. Amber Salzman's profile is kept up-to-date with the latest available information.

Last updated: July 27, 2026